1. Home
  2. CNA vs CYTK Comparison

CNA vs CYTK Comparison

Compare CNA & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CNA Financial Corporation

CNA

CNA Financial Corporation

N/A

Current Price

$47.36

Market Cap

13.1B

Sector

Finance

ML Signal

N/A

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

N/A

Current Price

$54.28

Market Cap

10.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CNA
CYTK
Founded
1853
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.1B
10.7B
IPO Year
1994
2004

Fundamental Metrics

Financial Performance
Metric
CNA
CYTK
Price
$47.36
$54.28
Analyst Decision
Buy
Analyst Count
0
22
Target Price
N/A
★ $107.39
AVG Volume (30 Days)
378.3K
★ 1.5M
Earning Date
11-02-2026
11-04-2026
Dividend Yield
★ 3.99%
N/A
EPS Growth
★ 33.24
N/A
EPS
★ 2.67
N/A
Revenue
★ $14,989,000,000.00
$13,368,000.00
Revenue This Year
$7.50
$79.67
Revenue Next Year
N/A
$172.23
P/E Ratio
$17.99
★ N/A
Revenue Growth
★ 5.04
N/A
52 Week Low
$41.53
$58.43
52 Week High
$55.71
$88.31

Technical Indicators

Market Signals
Indicator
CNA
CYTK
Relative Strength Index (RSI) 46.76 29.20
Support Level $47.09 N/A
Resistance Level $49.45 $66.93
Average True Range (ATR) 1.04 2.39
MACD -0.06 -0.35
Stochastic Oscillator 48.23 4.21

Price Performance

Historical Comparison
CNA
CYTK

About CNA CNA Financial Corporation

CNA Financial Corporation (CNAF) is an insurance holding company that provides commercial property and casualty insurance. The company operates under five segments: Specialty, Commercial and International being its core business, and two segments for its non-core businesses, which are Life and Group and Corporate and Other. CNAF, through its segments, provides professional, financial, specialty property, and casualty products to small businesses and medium-scale organizations. It has its business spread across Continental Europe, United Kingdom, and Canada. The majority of the revenues are generated from the Specialty and Commercial segment of the business.

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Share on Social Networks: